Tarapeutics Science Inc.

Anhui Agricultural University

Junjie Wang

Jing Liu

Li Wang

Qingsong Liu

Wenchao Wang

Beilei Wang

Cheng Chen

Ziping Qi

Shuang Qi

Yun Wu

Wenliang Wang

Fengming Zou

Zongru Jiang

Qingwang Liu

Xiaohong Lian

Tianyuan Yang

Xiaocao Luo

Xinpeng Zhao

Yunxia Xie

Xuesong Liu

Ziping Q

Zhaoliang Zhang

Xiaojuan Fan

Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.

Pan-KIT kinase inhibitor having quinoline structure and application thereof

Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.

MST1 kinase inhibitor and use thereof

The present disclosure provides a tea plant CsFAAH6 gene and use thereof. The tea plant CsFAAH6 gene has a nucleotide sequence shown in SEQ ID NO: 1 in sequence listing. A protein coded by the tea plant CsFAAH6 gene has an amino acid sequence shown in SEQ ID NO: 2 in the sequence listing. The CsFAAH6 is highly expressed in mature leaves of tea plants; there is significant negative correlation between theanine content in shoots (one bud and two leaves) of different tea cultivars in different months and expression level of the CsFAAH6; instantaneous silencing of CsFAAH6 expression can significantly increase the theanine content, indicating that CsFAAH6 has a physiological function of theanine degradation and a molecular mechanism thereof.

Tea plant CsFAAH6 gene and use thereof

Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 activity in a subject.

Indazole kinase inhibitor and use thereof

Growing community of inventors

Anhui, China

Junjie Wang